SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is under pressure after Q3 results highlighted weaker trading activity, with headline profit largely driven by gains on crypto holdings; the Binance hack and broader crypto weakness added to selling pressure. Traders are split between viewing the decline as a buying opportunity and worrying that soft volumes and shaken confidence in exchanges could prolong the downturn.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivians quarterly results beat expectations and the company raised its full-year delivery outlook as the R2 ramp gained traction, driving bullish discussion about improving execution and future growth. Traders remain divided, with some expecting a recovery while others point to continued cash burn and a muted share-price reaction.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

A Bank of America upgrade, citing DraftKings Predictions exchange as a potential growth opportunity, has fueled rebound interest after a steep selloff. Traders remain divided over whether rising exchange activity can offset regulatory uncertainty, competition from Kalshi and Polymarket, and pressure on the sportsbook business.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs REGAL Phase 3 AML trial reaching its 80-event milestone, which starts database lock, unblinding and final analysis, is drawing attention ahead of the expected topline results. Bulls point to the trials long duration and extended GPS dosing as possible signs of durable survival benefit, while skeptics question the dosing changes and trial design; the share-price decline has added to the debate.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

Biotechs sector-wide swings and rotation are driving attention, with traders weighing weakness tied to rising-rate concerns and money moving between biotech and tech against hopes for renewed inflows and M&A. The debate is whether the pullback is a deeper correction or a buying opportunity, with XBIs support levels and upcoming biotech catalysts in focus.

Corning, Inc. engages in the provision of glass for notebook computers, flat panel desktop monitors, display televisions, and other information display applications, carrier network and enterprise network products for the telecommunications industry, ceramic substrates for gasoline and diesel engines in automotive and heavy-duty vehicle markets, laboratory products for the scientific community and polymer products for biotechnology applications, optical materials for the semiconductor industry and the scientific community, and polycrystalline silicon products and other technologies. It operates through the following segments: Optical Communications, Display, Specialty Materials, Automotive, and Life Sciences. The Optical Communications segment is classified into two main product groupings: carrier and enterprise network. The carrier network group consists of products and solutions for optical-based communications infrastructure for services such as video, data, and voice communications. The enterprise network group consists primarily of optical-based communication networks sold to businesses, governments, and individuals for their own use. The Display Technologies segment manufactures glass substrates for flat panel displays, including organic light-emitting diodes and liquid crystal displays that are used primarily in televisions, notebook computers, desktop monitors, tablets, and handheld devices. The Specialty Materials segment is involved in the manufacture of products that provide material formulations for glass, glass ceramics and crystals, and precision metrology instruments and software. The Automotive segment manufactures ceramic substrates and filter products for emissions control in mobile applications around the world as well as technical glass and optic products and solutions for the interior and exterior of vehicles. The Life Sciences segment develops, manufactures, and supplies laboratory products. The company was founded by Amory Houghton Sr. in 1851 and is headquartered in Corning, NY.

Corning, Inc.

Cornings quarterly earnings beat and upbeat outlook, driven by AI-related optical communications demand, are being weighed against a sharp share-price pullback and bearish chart signals. Traders are split between viewing the decline as an overreaction to strong results and pointing to put-heavy options activity and broken support as signs of further near-term pressure.

Select Sector SPDR Trust (The) - State Street Consumer Staples Select Sector SPDR ETF

Consumer Staples Select Sector SPDR Fund

XLP is drawing attention as investors rotate toward defensive consumer staples amid weakness in technology and AI-related stocks, with traders highlighting the funds rebound toward record highs. The rally has prompted bullish technical commentary, while others caution that staples look stretched and the defensive trade may be crowded.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A sharp breakout to a 52-week high has focused attention on TGTX, with traders weighing BRIUMVIs sales momentum and Q3 results against anticipated subcutaneous BRIUMVI data. Buyout speculation and possible short covering are also prominent, but no acquisition is confirmed.

Shiba Inu (SHIB) is a cryptocurrency launched in 2020and operates on the Ethereum platform. Shiba Inu has a current supply of 589,495,715,255,345.65554501 with 589,238,256,711,817.89342663 in circulation. The last known price of Shiba Inu is 0.00000467 USD and is down -2.68 over the last 24 hours. It is currently trading on 1123 active market(s) with $35,462,996.64 traded over the last 24 hours. More information can be found at https://shibatoken.com/.

Shiba Inu

SHIB is drawing attention for choppy, largely range-bound trading, with repeated technical-chart posts describing consolidation and traders debating whether it can break resistance or resume falling. Long-term holders are buying dips and hoping for a meme-coin rally, while skeptics cite weak utility, token burns that have not shifted sentiment, and prolonged underperformance.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets, Data Centers, and Treasury and Corporate. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The Treasury and Corporate segment includes the company’s proprietary trading and mining activities, as well as the company’s principal investments and related gains and losses. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital is under pressure amid a broader crypto and AI data-center selloff, with traders especially focused on its reliance on CoreWeave as Helioss tenant and the lack of a new tenant announcement. Some see the strong quarterly results, buyback authorization, and data-center growth as support, while others worry about customer concentration, financing risks, and management credibility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

New Strong Sell Stocks for October 15th

CDZI, CNSY and CNTX have been added to the Zacks Rank #5 (Strong Sell) List on October 15, 2026.

New Strong Sell Stocks for October 13th

ATS, CANG and CNTX have been added to the Zacks Rank #5 (Strong Sell) List on October 13, 2026.

Maxim Says Context Therapeutics (CNTX)'s Share Pullback Is an Overreaction; Remains Bullish

Maxim Says Context Therapeutics (CNTX)'s Share Pullback Is an Overreaction; Remains Bullish...

CNTX Hits Worst Day In History After Ovarian Cancer Trial Data — But Analysts See Buying Opportunity In Dip

Equity

The Philadelphia biotech reported data from 21 patients with advanced CLDN6-positive solid tumors, including 14 with platinum-resistant ovarian cancer.


Context Therapeutics (NASDAQ:CNTX) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Context Therapeutics (NASDAQ:CNTX - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.03...

Context Therapeutics (CNTX) to Release Quarterly Earnings on Wednesday

Context Therapeutics (NASDAQ:CNTX) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at...

Context Therapeutics (NASDAQ:CNTX)  Shares Down 7%   - Time to Sell?

Context Therapeutics (NASDAQ:CNTX) Shares Down 7% - Here's What Happened...

Neogen Corporation Announces Appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary

Neogen Corporation (NASDAQ: NEOG), an innovative leader in food safety solutions, today announced the appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary. Ms. Stacey is an accomplished chief legal and compliance officer and board secretary with extensive...

Context Therapeutics (NASDAQ:CNTX) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen downgraded Context Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday...

Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the nine research firms that are currently covering the stock, MarketBeat...

Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.

Context Therapeutics Inc

Bullish Sentiment

<ul class="summary-bullets"><li>CEO Martin Lehr said the company remains encouraged by CTIM-76’s development as a potentially best-in-class option for patients with platinum-resistant ovarian cancer.</li><li>H.C. Wainwright analyst Emily Bodnar said the initial CTIM-76 data in heavily pretreated CLDN6-positive cancers suggest competitive activity relative to peers.&nbsp;</li><li>JonesResearch called the selloff a buying opportunity.&nbsp;</li></ul>Context Therapeutics (CNTX) shares plunged 51% on Monday after the company released interim early-stage results for its experimental cancer drug CTIM-76 which showed modest response rate from a small number of heavily pretreated individuals.The Philadelphia biotech reported data from 21 patients with advanced CLDN6-positive solid tumors, including 14 with platinum-resistant ovarian cancer. Among nine such ovarian cancer patients given active doses, seven were evaluable. Two achieved confirmed responses for a 29% overall response rate, while four showed disease control, the company said. These patients had received a median of seven prior therapies, with most having tried antibody-drug conjugates or targeted cancer therapies, it added.CEO Martin Lehr said the company remains encouraged by CTIM-76’s development as a potentially best-in-class option for patients with platinum-resistant ovarian cancer.The stock, however, clocked its worst day ever on Monday.<h2 class="st-heading-2">Wall Street Weighs In</h2>H.C. Wainwright analyst Emily Bodnar said the initial CTIM-76 data in heavily pretreated CLDN6-positive cancers, particularly platinum-resistant ovarian cancer, suggest competitive activity relative to peers despite a difficult patient population. Responses were seen even in patients previously treated with ADCs, the analyst noted. The firm maintains a ‘Buy’ rating and $5 price target.JonesResearch called the selloff a buying opportunity and described the early-stage update as “encouraging,” expecting further improvement in future data cuts. The firm noted the 29% response rate came in platinum-resistant ovarian cancer patients with a median of seven prior therapies versus a median of three in a Zymeworks (ZYME) study. It does not view the trials as comparable and keeps a ‘Buy’ rating with a $7 price target.<h2 class="st-heading-2">Other Near-Term Catalysts</h2>Context Therapeutics has two additional near-term clinical catalysts ahead. In September 2026, the company plans to release initial early-stage trial data from CT-95, its experimental drug being tested in patients with advanced solid tumors. Later in the third quarter, Context expects to begin dosing the first patient in an early-stage first-in-human study of its other investigational drug CT-202.<h2 class="st-heading-2">How Did CNTX Retail Traders React?</h2>On Stocktwits, retail sentiment around CNTX stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume jumped from ‘high’ to ‘extremely high’ levels.A Stocktwits user dismissed the Monday selloff as “exaggerated” and voiced hopes for a bounce-back.<stembedurl>https://www.stocktwits.com/TheJunksCalls/message/656495548</stembedurl>Another user flagged other potential near-term catalysts.<stembedurl>https://www.stocktwits.com/Biotech_Pharma_Investor/message/656481397</stembedurl><a href="https://stocktwits.com/symbol/CNTX">CNTX stock</a> has fallen 56% this year.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/cnc-stock-falls-as-centene-reportedly-eyes-employee-buyouts-amid-membership-decline/cZKfsojR73r">CNC Stock Falls 4% As Centene Reportedly Eyes Employee Buyouts Amid Membership Decline</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

The Philadelphia biotech reported data from 21 patients with advanced CLDN6-positive solid tumors, including 14 with platinum-resistant ovarian cancer.

Vanguard Total Stock Market ETF

Vanguard Extended Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

CNTX News